Comparative Pharmacology
Head-to-head clinical analysis: METHYLIN ER versus PEMOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLIN ER versus PEMOLINE.
METHYLIN ER vs PEMOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their availability in the synaptic cleft.
Pemoline is a central nervous system stimulant that enhances dopaminergic and noradrenergic transmission by blocking the reuptake of dopamine and norepinephrine at the synaptic cleft. It also has mild monoamine oxidase inhibitory activity.
20-60 mg orally once daily in the morning
Oral, 37.5 mg once daily in the morning; may increase by 18.75 mg weekly to a maximum of 112.5 mg/day (divided into 2 doses if total dose > 75 mg).
None Documented
None Documented
Mean 3-6 hours in adults; longer in children (4-8 hours). Clinical context: steady-state reached within 2 days; dosing every 8-12 hours.
Terminal elimination half-life is 8-12 hours in children; 12-16 hours in adults. Steady-state is reached within 2-3 days.
Renal (90% as metabolites, <1% unchanged). Biliary/fecal: <2%.
Pemoline is primarily excreted renally as unchanged drug (40-50%) and metabolites; approximately 20-30% is excreted in feces via biliary elimination.
Category C
Category C
CNS Stimulant
CNS Stimulant